AETHERA is a randomized, double-blind, placebo controlled multicenter Phase III study of brentuximab vedotin (SGN-35) in patients at high risk of residual Hodgkin lymphoma (HL) following stem cell treatment (NCT01100502).
The study recruited 329 patients aged 18 years or older with Hodgkin lymphoma who had received an autologous stem cell transplant (ASCT) in the previous 30-45 days, with adequate organ function. The trial evaluates the efficacy and safety of brentuximab vedotin, the best supportive care (BSC) compared to placebo, and the BSC in treatment of residual Hodgkin lymphoma following autologous stem cell transplant (ASCT).
VJHemOnc is intended for Healthcare Professionals only
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates
The content of VJHemOnc is intended for healthcare professionals